Nonparametric Bounds for Evaluating the Clinical Utility of Treatment Rules
By: Johannes Hruza , Erin Gabriel , Arvid Sjölander and more
Potential Business Impact:
Find best treatments even with missing info.
Evaluating the value of new clinical treatment rules based on patient characteristics is important but often complicated by hidden confounding factors in observational studies. Standard methods for estimating the average patient outcome if a new rule were universally adopted typically rely on strong, untestable assumptions about these hidden factors. This paper tackles this challenge by developing nonparametric bounds - a range of plausible values - for the expected outcome under a new rule, even with unobserved confounders present. We propose and investigate two main strategies for derivation of these bounds. We extend these techniques to incorporate Instrumental Variables (IVs), which can help narrow the bounds, and to directly estimate bounds on the difference in expected outcomes between the new rule and an existing clinical guideline. In simulation studies we compare the performance and width of bounds generated by the reduction and conditioning strategies in different scenarios. The methods are illustrated with a real-data example about prevention of peanut allergy in children. Our bounding frameworks provide robust tools for assessing the potential impact of new clinical treatment rules when unmeasured confounding is a concern.
Similar Papers
Nonparametric bounds for vaccine effects in randomized trials
Methodology
Finds vaccine's true protection, even if people know they got it.
Nonparametric estimation of an optimal treatment rule with fused randomized trials and missing effect modifiers
Applications
Finds best medicine for each patient.
Nonparametric Estimation of Local Treatment Effects with Continuous Instruments
Methodology
Helps doctors understand how treatments really work.